Prudential Financial
ARQT icon

Prudential Financial’s Arcutis Biotherapeutics ARQT Stock Holding History

Prudential Financial’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$679K Sell
25,915
-230,630
-90% -$5.37M ﹤0.01% 1804
2026
Q1 		$6.04M Buy
256,545
+21,630
+9% +$552K 0.01% 843
2025
Q4 		$6.82M Buy
234,915
+220,980
+1,586% +$5.66M 0.01% 786
2025
Q3 		$263K Sell
13,935
-584,965
-98% -$9.23M ﹤0.01% 2136
2025
Q2 		$8.4M Buy
598,900
+5,705
+1% +$80K 0.01% 703
2025
Q1 		$9.28M Buy
593,195
+630
+0.1% +$8.88K 0.01% 612
2024
Q4 		$8.25M Buy
592,565
+19,950
+3% +$219K 0.01% 686
2024
Q3 		$5.33M Hold
572,615
– – 0.01% 970
2024
Q2 		$5.33M Sell
572,615
-150,710
-21% -$1.36M 0.01% 895
2024
Q1 		$7.17M Sell
723,325
-94,730
-12% -$707K 0.01% 784
2023
Q4 		$2.64M Buy
818,055
+454,640
+125% +$1.24M ﹤0.01% 1266
2023
Q3 		$2.01M Hold
363,415
– – ﹤0.01% 1364
2023
Q2 		$3.46M Buy
363,415
+200,585
+123% +$2.23M 0.01% 1095
2023
Q1 		$1.79M Buy
162,830
+65,975
+68% +$954K ﹤0.01% 1409
2022
Q4 		$1.43M Buy
96,855
+30,020
+45% +$524K ﹤0.01% 1510
2022
Q3 		$1.28M Buy
66,835
+340
+0.5% +$7.7K ﹤0.01% 1619
2022
Q2 		$1.42M Buy
+66,495
New +$1.36M ﹤0.01% 1592

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Prudential Financial's ARQT Position: Q2 2026 in Review

Prudential Financial reduced its Arcutis Biotherapeutics (ARQT) stake by 90% in Q2 2026, selling an estimated $5.37M and leaving 25,915 shares worth $679K. The position accounts for ﹤0.01% of the portfolio, ranked #1804.

Prudential Financial first reported a position in ARQT in Q2 2022 and has held it in 17 quarters since. The position peaked at $9.28M in Q1 2025. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Prudential Financial held 25,915 shares of Arcutis Biotherapeutics worth $679K as of Q2 2026.
  • Prudential Financial sold 230,630 Arcutis Biotherapeutics shares in Q2 2026, an estimated $5.37M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q2 2026, its #1804 holding.
  • Prudential Financial first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 17 quarters since.
  • Prudential Financial's Arcutis Biotherapeutics position peaked at $9.28M in Q1 2025.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.